Literature DB >> 18243043

TLR-mediated immune responses in the urinary tract.

Jeongmin Song1, Soman N Abraham.   

Abstract

The urinary tract is one of the most intractable mucosal surfaces for pathogens to colonize. In addition to the natural barriers at this site, potential pathogens have to contend with the vigorous local innate immune system. Several Toll-like receptors (TLRs) have been identified on epithelial cells of the bladder and the kidneys which mediate a variety of powerful immune responses. A common finding among successful uropathogens is their intrinsic ability to suppress TLR-mediated responses. As antibiotic therapy becomes increasingly ineffective, employing boosters of the innate immune system in the urinary tract may become a viable option.

Mesh:

Substances:

Year:  2008        PMID: 18243043      PMCID: PMC2775047          DOI: 10.1016/j.mib.2007.12.001

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  43 in total

Review 1.  Raft membrane domains: from a liquid-ordered membrane phase to a site of pathogen attack.

Authors:  F G van der Goot; T Harder
Journal:  Semin Immunol       Date:  2001-04       Impact factor: 11.130

Review 2.  Microbial entry through caveolae: variations on a theme.

Authors:  Matthew J Duncan; Jeoung-Sook Shin; Soman N Abraham
Journal:  Cell Microbiol       Date:  2002-12       Impact factor: 3.715

3.  Cytokine repertoire of epithelial cells lining the human urinary tract.

Authors:  L Hang; B Wullt; Z Shen; D Karpman; C Svanborg
Journal:  J Urol       Date:  1998-06       Impact factor: 7.450

Review 4.  Diagnosis and treatment of uncomplicated urinary tract infection.

Authors:  T M Hooton; W E Stamm
Journal:  Infect Dis Clin North Am       Date:  1997-09       Impact factor: 5.982

5.  Bacterial invasion augments epithelial cytokine responses to Escherichia coli through a lipopolysaccharide-dependent mechanism.

Authors:  J D Schilling; M A Mulvey; C D Vincent; R G Lorenz; S J Hultgren
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

Review 6.  Bad bugs and beleaguered bladders: interplay between uropathogenic Escherichia coli and innate host defenses.

Authors:  M A Mulvey; J D Schilling; J J Martinez; S J Hultgren
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

7.  CD14- and Toll-like receptor-dependent activation of bladder epithelial cells by lipopolysaccharide and type 1 piliated Escherichia coli.

Authors:  Joel D Schilling; Steven M Martin; David A Hunstad; Kunal P Patel; Matthew A Mulvey; Sheryl S Justice; Robin G Lorenz; Scott J Hultgren
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

8.  Selective cytokine production by epithelial cells following exposure to Escherichia coli.

Authors:  W Agace; S Hedges; U Andersson; J Andersson; M Ceska; C Svanborg
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

9.  Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding.

Authors:  G Zhou; W J Mo; P Sebbel; G Min; T A Neubert; R Glockshuber; X R Wu; T T Sun; X P Kong
Journal:  J Cell Sci       Date:  2001-11       Impact factor: 5.285

10.  Integrin-mediated host cell invasion by type 1-piliated uropathogenic Escherichia coli.

Authors:  Danelle S Eto; Tiffani A Jones; Jamie L Sundsbak; Matthew A Mulvey
Journal:  PLoS Pathog       Date:  2007-07       Impact factor: 6.823

View more
  36 in total

Review 1.  Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.

Authors:  Thomas J Hannan; Makrina Totsika; Kylie J Mansfield; Kate H Moore; Mark A Schembri; Scott J Hultgren
Journal:  FEMS Microbiol Rev       Date:  2012-05       Impact factor: 16.408

Review 2.  The role of Toll-like receptors in renal diseases.

Authors:  Anna Gluba; Maciej Banach; Simon Hannam; Dimitri P Mikhailidis; Agata Sakowicz; Jacek Rysz
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

Review 3.  Cell biology and physiology of the uroepithelium.

Authors:  Puneet Khandelwal; Soman N Abraham; Gerard Apodaca
Journal:  Am J Physiol Renal Physiol       Date:  2009-07-08

4.  Genomic diversity and fitness of E. coli strains recovered from the intestinal and urinary tracts of women with recurrent urinary tract infection.

Authors:  Swaine L Chen; Meng Wu; Jeffrey P Henderson; Thomas M Hooton; Michael E Hibbing; Scott J Hultgren; Jeffrey I Gordon
Journal:  Sci Transl Med       Date:  2013-05-08       Impact factor: 17.956

Review 5.  Sleeping beauty: awakening urothelium from its slumber.

Authors:  Zarine R Balsara; Xue Li
Journal:  Am J Physiol Renal Physiol       Date:  2017-01-25

6.  Regulation of cytotoxic T lymphocyte antigen 4 by cyclic AMP.

Authors:  Jinghong Li; Ko-Wei Lin; Fiona Murray; Takeshi Nakajima; Yandong Zhao; David L Perkins; Patricia W Finn
Journal:  Am J Respir Cell Mol Biol       Date:  2012-09-28       Impact factor: 6.914

Review 7.  The pathogenesis and management of renal scarring in children with vesicoureteric reflux and pyelonephritis.

Authors:  Vasikar Murugapoopathy; Christine McCusker; Indra R Gupta
Journal:  Pediatr Nephrol       Date:  2019-03-07       Impact factor: 3.714

8.  Inflammasomes are important mediators of cyclophosphamide-induced bladder inflammation.

Authors:  Francis M Hughes; Nivardo P Vivar; James G Kennis; Jeffery D Pratt-Thomas; Danielle W Lowe; Brooke E Shaner; Paul J Nietert; Laura S Spruill; J Todd Purves
Journal:  Am J Physiol Renal Physiol       Date:  2013-11-27

9.  Association of Toll-like receptor 4 gene polymorphism and expression with urinary tract infection types in adults.

Authors:  Xiaolin Yin; Tianwen Hou; Ying Liu; Jing Chen; Zhiyan Yao; Cuiqing Ma; Lijuan Yang; Lin Wei
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

Review 10.  Toll-like receptors in kidney disease.

Authors:  Kelly D Smith
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-05       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.